Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.51 |
| ▸ | CDK4 | P11802 | 5/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.51 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.45 |
| ▸ | JAK2 | O60674 | 4/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7975412 | 0.92 | CDK2 (0.54) | CDK2CDK4CCNE1CAMK2DCDK1 | |
| SCHEMBL701721 | 0.87 | CDK2 (0.55) | CDK2CDK4CCNE1CAMK2DHDAC1 | |
| SCHEMBL699883 | 0.87 | HDAC1 (0.61) | CDK2CDK4CCNE1HDAC1JAK2 | |
| SCHEMBL699814 | 0.85 | CDK2 (0.51) | CDK2CDK4CCNE1CAMK2DHDAC1 | |
| SCHEMBL699629 | 0.85 | CDK2 (0.51) | CDK2CDK4CCNE1CAMK2DHDAC1 | |
| SCHEMBL699170 | 0.85 | CDK2 (0.50) | CDK2CDK4CCNE1CAMK2DHDAC1 | |
| SCHEMBL699562 | 0.84 | CDK2 (0.73) | CDK2CDK4CCNE1CAMK2DHDAC1 | |
| SCHEMBL701162 | 0.84 | HDAC1 (0.58) | CDK2CDK4CCNE1CAMK2DHDAC1 | |
| SCHEMBL700744 | 0.83 | CDK2 (0.49) | CDK2CDK4CCNE1CDK1 | |
| SCHEMBL700837 | 0.82 | CDK2 (0.48) | CDK2CDK4CCNE1CAMK2DHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | CDK2 16/4885CDK4 15/4885CCNE1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.